Trial
NCT05288543
A Study of Orally Administered IPG7236 in Healthy Adult Participants
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Nanjing Immunophage Biotech Co., Ltd
Collaborators
Novotech (Australia) Pty Limited
Condition
Atopic Dermatitis
Intervention
IPG7236- Single ascending dose
Why stopped
Sponsor decision
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-12-22